Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (148) 148
life sciences & biomedicine (125) 125
humans (102) 102
male (79) 79
female (77) 77
electricity (68) 68
middle aged (63) 63
physics (58) 58
aged (56) 56
performing operations (55) 55
transporting (55) 55
general tagging of cross-sectional technologies spanning over several sections of the ipc (47) 47
general tagging of new technological developments (47) 47
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (47) 47
oncology (46) 46
chemistry (45) 45
technologies or applications for mitigation or adaptation againstclimate change (41) 41
adult (40) 40
biological and medical sciences (37) 37
hematology (35) 35
metallurgy (35) 35
medical sciences (34) 34
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (33) 33
basic electric elements (32) 32
blasting (31) 31
heating (31) 31
lighting (31) 31
mechanical engineering (31) 31
weapons (31) 31
conversion or distribution of electric power (28) 28
generation (28) 28
human necessities (28) 28
animals (26) 26
physical sciences (26) 26
dynamo-electric machines (25) 25
treatment outcome (24) 24
medicine & public health (23) 23
aged, 80 and over (22) 22
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (22) 22
hematologic and hematopoietic diseases (18) 18
hygiene (18) 18
lining machines (18) 18
printing (18) 18
stamps (18) 18
typewriters (18) 18
correction of typographical errors (17) 17
i.e. mechanisms printing otherwise than from a forme (17) 17
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (17) 17
medical or veterinary science (17) 17
medical research (17) 17
patients (17) 17
selective printing mechanisms (17) 17
climate change mitigation technologies related totransportation (16) 16
recurrence (16) 16
surgery (16) 16
tumors (16) 16
care and treatment (15) 15
compositions based thereon (15) 15
lymphoma (15) 15
measuring (15) 15
organic macromolecular compounds (15) 15
testing (15) 15
their preparation or chemical working-up (15) 15
aeroplanes (14) 14
aircraft (14) 14
analysis (14) 14
aviation (14) 14
cosmonautics (14) 14
fixed constructions (14) 14
helicopters (14) 14
medicine, experimental (14) 14
transplantation (14) 14
abridged index medicus (13) 13
building (13) 13
clinical trials (13) 13
japan (13) 13
mice (13) 13
original (13) 13
adhesives (12) 12
calculating (12) 12
chemotherapy (12) 12
computing (12) 12
counting (12) 12
investigating or analysing materials by determining theirchemical or physical properties (12) 12
macromolecular compounds obtained by reactions only involvingcarbon-to-carbon unsaturated bonds (12) 12
optics (12) 12
organic chemistry (12) 12
research (12) 12
rituximab (12) 12
stem cells (12) 12
urology & nephrology (12) 12
antineoplastic agents (11) 11
antineoplastic agents - therapeutic use (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
ceilings (11) 11
chemical paint or ink removers (11) 11
coating compositions, e.g. paints, varnishes orlacquers (11) 11
correcting fluids (11) 11
dyes (11) 11
filling pastes (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (535) 535
Japanese (52) 52
French (31) 31
German (12) 12
Korean (7) 7
Chinese (6) 6
Danish (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
by Tobinai, Kensei and Uchida, Toshiki and Fukuhara, Noriko and Nishikawa, Tomoaki
International journal of hematology, ISSN 0925-5710, 3/2019, Volume 109, Issue 3, pp. 366 - 368
Medicine & Public Health | Hematology | Oncology | Life Sciences & Biomedicine | Science & Technology | Asian Continental Ancestry Group | Pyrazoles - administration & dosage | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Japan | Pyrimidines - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Female | Male | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazoles - adverse effects | Analysis | Cancer | Lymphocytes B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
by Ogura, Michinori and Uchida, Toshiki and Terui, Yasuhito and Hayakawa, Fumihiko and Kobayashi, Yukio and Taniwaki, Masafumi and Takamatsu, Yasushi and Naoe, Tomoki and Tobinai, Kensei and Munakata, Wataru and Yamauchi, Takeshi and Kageyama, Akiko and Yuasa, Miyuki and Motoyama, Masaaki and Tsunoda, Takeshi and Hatake, Kiyohiko
Cancer science, ISSN 1347-9032, 07/2015, Volume 106, Issue 7, pp. 896 - 901
Daily dosing schedule | phase I study | hematological malignancy | STAT3 inhibitor | OPB‐51602 | Phase I study | OPB-51602 | Hematological malignancy | Life Sciences & Biomedicine | Oncology | Science & Technology | Peripheral Nervous System Diseases - chemically induced | Phosphorylation | Nausea - chemically induced | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - toxicity | Maximum Tolerated Dose | Multiple Myeloma - drug therapy | Protein Processing, Post-Translational - drug effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacokinetics | STAT3 Transcription Factor - antagonists & inhibitors | STAT3 Transcription Factor - metabolism | Lymphoma, Non-Hodgkin - drug therapy | Transcription | Leukemia | Multiple myeloma | Myeloma | Peripheral neuropathy | Signal transduction | Bone marrow | Lactic acidosis | Neutropenia | Thrombocytopenia | Leukopenia | Hematology | Myeloid leukemia | Diarrhea | Nausea | Patients | Lymphoma | Studies | Lymphopenia | Antitumor activity | Lactic acid | Pharmacokinetics | Acidosis | Acute myeloid leukemia | Pharmaceuticals | Tumors | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I study
by Ohmachi, Ken and Ando, Kiyoshi and Ogura, Michinori and Uchida, Toshiki and Tobinai, Kensei and Maruyama, Dai and Namiki, Masayuki and Nakanishi, Tadashi
Cancer science, ISSN 1347-9032, 03/2018, Volume 109, Issue 3, pp. 794 - 802
peripheral T‐cell lymphoma | cutaneous T‐cell lymphoma | Japanese patients | E7777 | phase I study | peripheral T-cell lymphoma | cutaneous T-cell lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Drug Administration Schedule | Administration, Oral | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Lymphoma, T-Cell, Cutaneous - drug therapy | Young Adult | Diphtheria Toxin - therapeutic use | Maximum Tolerated Dose | Interleukin-2 - administration & dosage | Adult | Female | Aged | Infusions, Intravenous | Recombinant Fusion Proteins - administration & dosage | Cohort Studies | Interleukins | T cells | Non-Hodgkin's lymphomas | Cytotoxicity | Kinases | Lipase | Proteins | Hypokalemia | CD25 antigen | Fusion protein | Diphtheria toxin | Pharmaceutical industry | Drug dosages | Appetite | Alanine | Hyponatremia | Cytokines | Research funding | Amino acid sequence | Fatigue | Diphtheria | Lymphoma | Studies | Hospitals | Lymphopenia | Medical prognosis | Alanine transaminase | Antitumor activity | Pharmacokinetics | Tumors | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma
by Ohmachi, Ken and Ogura, Michinori and Suehiro, Youko and Ando, Kiyoshi and Uchida, Toshiki and Choi, Ilseung and Ogawa, Yoshiaki and Kobayashi, Miki and Fukino, Koichi and Yokoi, Yuki and Okamura, Jun
International journal of hematology, ISSN 0925-5710, 06/2019, Volume 109, Issue 6, pp. 657 - 664
Life Sciences & Biomedicine | Hematology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Recurrence | Humans | Middle Aged | Male | Treatment Outcome | Asian Continental Ancestry Group | Multiple Myeloma - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Aged, 80 and over | Adult | Female | Aged | Infusions, Intravenous | Antigens, CD19 - immunology | Lymphoma, B-Cell - drug therapy | Monoclonal antibodies | Transplantation | Lymphomas | Leukemia | Hematopoietic stem cells | Chronic lymphatic leukemia | CD19 antigen | Leukopenia | Toxicity | Multiple myeloma | Stem cell transplantation | Pharmacology | Lymphatic leukemia | Dosage | Patients | Lymphoma | Hemopoiesis | Anticancer properties | Infusion | Antitumor agents | Lymphocytes B | Stem cells | Pharmacokinetics | Neutropenia | B-cell lymphoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by Ken Ohmachi and Nozomi Niitsu and Toshiki Uchida and Seok Jin Kim and Kiyoshi Ando and Naoki Takahashi and Naoto Takahashi and Naokuni Uike and Hyeon Seok Eom and Yee Soo Chae and Takashi Terauchi and Ukihide Tateishi and Mitsuaki Tatsumi and Won Seog Kim and Kensei Tobinai and Cheolwon Suh and Michinori Ogura
Journal of clinical oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2103 - 2109
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Recurrence | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - surgery | Lymphoma, Large B-Cell, Diffuse - pathology | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Rituximab | Male | Nitrogen Mustard Compounds - adverse effects | Remission Induction | Stem Cell Transplantation | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
by Shigeru Kusumoto and Yasuhito Tanaka and Ritsuro Suzuki and Takashi Watanabe and Masanobu Nakata and Hirotaka Takasaki and Noriyasu Fukushima and Takuya Fukushima and Yukiyoshi Moriuchi and Kuniaki Itoh and Kisato Nosaka and Ilseung Choi and Masashi Sawa and Rumiko Okamoto and Hideki Tsujimura and Toshiki Uchida and Sachiko Suzuki and Masataka Okamoto and Tsutomu Takahashi and Isamu Sugiura and Yasushi Onishi and Mika Kohri and Shinichiro Yoshida and Rika Sakai and Minoru Kojima and Hiroyuki Takahashi and Akihiro Tomita and Dai Maruyama and Yoshiko Atsuta and Eiji Tanaka and Takayo Suzuki and Tomohiro Kinoshita and Michinori Ogura and Masashi Mizokami and Ryuzo Ueda
Clinical infectious diseases, ISSN 1058-4838, 9/2015, Volume 61, Issue 5, pp. 719 - 729
ARTICLES AND COMMENTARIES | Resolved HBV infection | Rituximab | HBV DNA monitoring | Preemptive antiviral therapy | HBV reactivation | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Lymphoma, B-Cell - complications | Prospective Studies | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepatitis B - virology | Hepatitis B - epidemiology | Male | Lymphoma, B-Cell - epidemiology | DNA, Viral - blood | Hepatitis B - complications | Antiviral Agents - adverse effects | Hepatitis B - drug therapy | Hepatitis B virus - genetics | Female | Lymphoma, B-Cell - virology | Aged | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis B virus | Research | Hepatitis B | Hepatitis | Antigens | Surveillance | Lymphoma | Risk factors | Deoxyribonucleic acid--DNA | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report
by Nakamae, Hirohisa and Fujisawa, Shin and Ogura, Michinori and Uchida, Toshiki and Onishi, Yasushi and Taniwaki, Masafumi and Utsunomiya, Atae and Matsue, Kosei and Takamatsu, Yasushi and Usuki, Kensuke and Tanimoto, Mitsune and Ishida, Yoji and Ohashi, Kazuteru and Li, Li and Miyoshi, Masafumi
International journal of hematology, ISSN 0925-5710, 06/2017, Volume 105, Issue 6, pp. 792 - 804
Dasatinib | Imatinib | CML | Tyrosine kinase inhibitor | Japan | Life Sciences & Biomedicine | Hematology | Science & Technology | Japan - epidemiology | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Survival Rate | Disease-Free Survival | Asian Continental Ancestry Group | Dasatinib - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Imatinib Mesylate - administration & dosage | Adult | Female | Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Antimitotic agents | Tyrosine | Medical colleges | Medical research | Resveratrol | Clinical trials | Medicine, Experimental | Chronic myeloid leukemia | Antineoplastic agents | Hands | Slopes | Cornea | Effectiveness | Myeloid leukemia | Leukemia | Pleural effusion | Patients | Survival | Health care delivery | Safety | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies
by Tobinai, Kensei and Tobinai, Kensei and Ogura, Michinori and Ogura, Michinori and Ishizawa, Kenichi and Ishizawa, Kenichi and Suzuki, Tatsuya and Suzuki, Tatsuya and Munakata, Wataru and Munakata, Wataru and Uchida, Toshiki and Uchida, Toshiki and Aoki, Tomohiro and Aoki, Tomohiro and Morishita, Takanobu and Morishita, Takanobu and Ushijima, Yoko and Ushijima, Yoko and Takahara, Satoko and Takahara, Satoko
International journal of hematology, ISSN 0925-5710, 1/2016, Volume 103, Issue 1, pp. 86 - 94
B cell malignancies | Covalent BTK inhibitor | Medicine & Public Health | Hematology | Oncology | Safety | Japanese | Ibrutinib | Life Sciences & Biomedicine | Science & Technology | Recurrence | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Pyrazoles - pharmacokinetics | Lymphoma, B-Cell - drug therapy | Pyrazoles - adverse effects | Enzyme Inhibitors - adverse effects | Pyrimidines - administration & dosage | Treatment Outcome | Asian Continental Ancestry Group | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Protein-Tyrosine Kinases - antagonists & inhibitors | Medical colleges | Pneumonia | Safety and security measures | Anemia | Bacterial pneumonia | Lymphomas | Bilirubin | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
by Fujishima, Naohito and Uchida, Toshiki and Onishi, Yasushi and Jung, Chul Won and Goh, Yeow Tee and Ando, Kiyoshi and Wang, Ming Chung and Ono, Chiho and Matsumizu, Miyako and Paccagnella, M Luisa and Sleight, Barbara and Vandendries, Erik and Fujii, Yosuke and Hino, Masayuki
International journal of hematology, ISSN 0925-5710, 12/2019, Volume 110, Issue 6, pp. 709 - 722
Medicine & Public Health | Hematology | Acute lymphoblastic leukemia | Oncology | Inotuzumab ozogamicin | Asian | Relapsed/refractory | Life Sciences & Biomedicine | Science & Technology | Inotuzumab Ozogamicin - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications | Salvage Therapy - adverse effects | Hepatic Veno-Occlusive Disease - etiology | Standard of Care | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Inotuzumab Ozogamicin - adverse effects | Neoplasm, Residual | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Asian Continental Ancestry Group | Salvage Therapy - standards | Adult | Female | Remission Induction - methods | Salvage Therapy - methods | Medical colleges | Transplantation | Acute lymphocytic leukemia | Analysis | Hematopoietic stem cells | Acute lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Stem cell transplantation | International standardization | Lymphatic leukemia | Patients | Subgroups | Hemopoiesis | Randomization | Lymphocytes B | Stem cells | Remission | Safety | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Aggregation-induced emission effect on turn-off fluorescent switching of a photochromic diarylethene
by Kono, Luna and Nakagawa, Yuma and Fujimoto, Ayako and Nishimura, Ryo and Hattori, Yohei and Mutai, Toshiki and Yasuda, Nobuhiro and Koizumi, Kenichi and Yokojima, Satoshi and Nakamura, Shinichiro and Uchida, Kingo
Beilstein journal of organic chemistry, ISSN 1860-5397, 09/2019, Volume 15, Issue 1, pp. 2204 - 2212
Physical Sciences | Chemistry | Chemistry, Organic | Science & Technology | Solvents | Aqueous solutions | U.V. radiation | Light | Crystals | Fluorescence | Isomers | esipt fluorescent switching | turn-off fluorescence | aie | diarylethene
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
by Maruyama, Dai and Nagai, Hirokazu and Fukuhara, Noriko and Kitano, Toshiyuki and Ishikawa, Takayuki and Shibayama, Hirohiko and Choi, Ilseung and Hatake, Kiyohiko and Uchida, Toshiki and Nishikori, Momoko and Kinoshita, Tomohiro and Matsuno, Yoshihiro and Nishikawa, Tomoaki and Takahara, Satoko and Tobinai, Kensei
Cancer science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1785 - 1790
ibrutinib | Efficacy | mantle cell lymphoma | safety | overall response rate | Life Sciences & Biomedicine | Oncology | Science & Technology | Recurrence | Pyrazoles - therapeutic use | Humans | Middle Aged | Lymphoma, Mantle-Cell - pathology | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Lymphoma, Mantle-Cell - mortality | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Pyrazoles - adverse effects | Pyrimidines - administration & dosage | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Protein Kinase Inhibitors - administration & dosage | Retreatment | Pyrazoles - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Medical research | Relapse | Anemia | Medicine, Experimental | Development and progression | Lymphomas | Censorship | Diseases | Hematology | Toxicity | Research & development--R&D | Oral administration | Diarrhea | Patients | Lymphoma | Stomatitis | Chemotherapy | Mantle cell lymphoma | Cell cycle | Sepsis | Safety | Pharmaceuticals | Neutropenia | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights